Catalent Inc
$
46
-0.01 (-0.02%)
| Volume: | 278,352 | Avg Vol (1m): | 788,313 |
| Market Cap $: | 6.73 Bil | Enterprise Value $: | 8.69 Bil |
| P/E (TTM): | 43.60 | P/B: | 4.19 |
| Earnings Power Value | 3.91 |
| Net Current Asset Value | -11.78 |
| Tangible Book | -2.34 |
| Projected FCF | 14.32 |
| Median P/S Value | 34.21 |
| Graham Number | 0 |
| Peter Lynch Value | 0 |
| DCF (FCF Based) | 0 |
| DCF (Earnings Based) | 0 |
1Y (-%)
Add to portfolio
Email alerts
Stock PDF
RSS
Website
Filings
Download Excel
Batch Download
Manual of Stocks™ Web
Manual of Stocks™
Manual of Stocks™ Web
Manual of Stocks™
Financial Strength : 5/10
GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| Current | vs industry | vs history | |
|---|---|---|---|
| Cash-to-Debt | 0.10 |
Cash-To-Debt ranked
lower than
87.89%
of
859
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 91151, Med: 2.03, Min: -0.01
CTLT:
0.1
Ranked among companies with meaningful Cash-To-Debt only.
|
Cash-To-Debt range over the past 10 years
Min: 0.02, Med: 0.07, Max: 0.29
Current: 0.1
|
| Equity-to-Asset | 0.36 |
Equity-to-Asset ranked
lower than
90.61%
of
788
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 1.78, Med: 0.64, Min: -27.83
CTLT:
0.36
Ranked among companies with meaningful Equity-to-Asset only.
|
Equity-to-Asset range over the past 10 years
Min: -0.14, Med: 0.2, Max: 0.36
Current: 0.36
|
| Debt-to-Equity | 1.35 |
Debt-to-Equity ranked
lower than
96.81%
of
596
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 31.22, Med: 0.32, Min: 0.01
CTLT:
1.35
Ranked among companies with meaningful Debt-to-Equity only.
|
Debt-to-Equity range over the past 10 years
Min: -7.65, Med: 2.73, Max: 4.02
Current: 1.35
|
| Debt-to-EBITDA | 4.32 |
Debt-to-EBITDA ranked
lower than
83.03%
of
495
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 343059.67, Med: 1.92, Min: 0.01
CTLT:
4.32
Ranked among companies with meaningful Debt-to-EBITDA only.
|
Debt-to-EBITDA range over the past 10 years
Min: 4.32, Med: 6, Max: 8.12
Current: 4.32
|
| Interest Coverage | 2.64 |
Interest Coverage ranked
lower than
89.35%
of
648
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 2689668, Med: 86.08, Min: 0.01
CTLT:
2.64
Ranked among companies with meaningful Interest Coverage only.
|
Interest Coverage range over the past 10 years
Min: 1.12, Med: 2.11, Max: 2.8
Current: 2.64
|
| Piotroski F-Score | 6 |
0
1
2
3
4
5
6
7
8
9
| |
| Altman Z-Score | 2.06 |
DISTRESS
GREY
SAFE
| |
| Beneish M-Score | -2.44 |
Not Manipulator
Manipulator
| |
| WACC vs ROIC % |
ROIC 7.28%
WACC 11.49%
| ||
Profitability & Growth : 7/10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
| Current | vs industry | vs history | |
|---|---|---|---|
| Operating Margin % | 11.73 |
Operating Margin ranked
higher than
62.55%
of
801
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 8950, Med: 7.97, Min: -232970.37
CTLT:
11.73
Ranked among companies with meaningful Operating Margin only.
|
Operating Margin range over the past 10 years
Min: 11.73, Med: 12.8, Max: 15.18
Current: 11.73
|
| Net Margin % | 6.01 |
Net Margin ranked
lower than
60.47%
of
802
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 304900, Med: 5.32, Min: -216285.19
CTLT:
6.01
Ranked among companies with meaningful Net Margin only.
|
Net Margin range over the past 10 years
Min: -3.53, Med: 2.14, Max: 11.59
Current: 6.01
|
| ROE % | 10.85 |
ROE ranked
higher than
53.73%
of
832
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 316.96, Med: 5.94, Min: -3119.47
CTLT:
10.85
Ranked among companies with meaningful ROE only.
|
ROE range over the past 10 years
Min: 9.24, Med: 16.86, Max: 161.49
Current: 10.85
|
| ROA % | 3.31 |
ROA ranked
lower than
56.14%
of
871
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 943.36, Med: 2.88, Min: -1851.14
CTLT:
3.31
Ranked among companies with meaningful ROA only.
|
ROA range over the past 10 years
Min: -1.63, Med: 2.09, Max: 6.81
Current: 3.31
|
| ROC (Joel Greenblatt) % | 17.01 |
ROC (Joel Greenblatt) ranked
higher than
65.38%
of
855
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 34233.33, Med: 11.23, Min: -2671900
CTLT:
17.01
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
|
ROC (Joel Greenblatt) range over the past 10 years
Min: 17.01, Med: 20.19, Max: 41.21
Current: 17.01
|
| 3-Year Total Revenue Growth Rate | 10.40 |
3-Year Revenue Growth Rate ranked
lower than
86.79%
of
689
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 291.9, Med: 5.8, Min: -100
CTLT:
7
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
|
3-Year Revenue Growth Rate range over the past 10 years
Min: -1.5, Med: 1.7, Max: 7
Current: 7
|
| 3-Year Total EBITDA Growth Rate | 8.20 |
3-Year EBITDA Growth Rate ranked
lower than
84.66%
of
704
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 299.6, Med: 7.3, Min: -343.2
CTLT:
4.9
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
|
3-Year EBITDA Growth Rate range over the past 10 years
Min: -2.6, Med: 1.7, Max: 10.7
Current: 4.9
|
| 3-Year EPS w/o NRI Growth Rate | -28.90 |
3-Year EPS w/o NRI Growth Rate ranked
higher than
88.69%
of
663
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 385.8, Med: 8.9, Min: -403.2
CTLT:
-28.9
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
| N/A |
» CTLT's 30-Y Financials
Financials (Next Earnings Date: 2019-08-28)
Guru Trades Click for details
Guru Trades in
SEC Filings
Gurus Latest Trades with NYSE:CTLT
» Interactive Chart
Peter Lynch Chart
Business Description
| Industry | Drug Manufacturers » Drug Manufacturers - Specialty & Generic   NAICS : 325412   SIC : 2834 |
| Compare | NSE:DIVISLAB SHSE:600085 OSTO:SOBI BOM:500124 NSE:AUROPHARMA NYSE:PRGO TSE:4508 SZSE:300142 SZSE:002001 SZSE:000963 TSE:4581 BOM:500257 TSX:CRON SZSE:002773 LSE:HIK SHSE:600518 NAS:TLRY SHSE:600535 TSX:BHC SZSE:300601 |
| Traded in other countries | 0C8.Germany |
| Address | 14 Schoolhouse Road, Somerset, NJ, USA, 08873 |
| Catalent is a specialty and generic drug manufacturing company. The company focuses on advanced delivery technologies and development solutions for drugs, biologics, and consumer health products. The vast majority of Catalent's sales are generated in the United States, followed by Europe and the rest of the world. Most of the company's sales are derived from branded drug products. The company considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. | |
Ratios
| Current | vs industry | vs history | |
|---|---|---|---|
| PE Ratio (TTM) | 43.60 |
PE Ratio ranked
lower than
90.48%
of
557
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 1910, Med: 23.77, Min: 0.06
CTLT:
43.6
Ranked among companies with meaningful PE Ratio only.
|
PE Ratio range over the past 10 years
Min: 12.04, Med: 38.83, Max: 159.94
Current: 43.6
|
| Forward PE Ratio | 22.88 |
Forward P/E ranked
higher than
52.25%
of
111
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 322.58, Med: 21.6, Min: 5.03
CTLT:
22.88
Ranked among companies with meaningful Forward P/E only.
| N/A |
| PE Ratio without NRI | 43.60 |
PE without NRI ranked
lower than
90.11%
of
556
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 2125, Med: 24.2, Min: 0.06
CTLT:
43.6
Ranked among companies with meaningful PE without NRI only.
|
PE without NRI range over the past 10 years
Min: 12.04, Med: 38.91, Max: 169.35
Current: 43.6
|
| Price-to-Owner-Earnings | 54.30 |
Price-to-Owner-Earnings ranked
lower than
51.85%
of
324
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 3160, Med: 31.95, Min: 0.17
CTLT:
54.3
Ranked among companies with meaningful Price-to-Owner-Earnings only.
|
Price-to-Owner-Earnings range over the past 10 years
Min: 23.43, Med: 30.7, Max: 60.06
Current: 54.3
|
| PB Ratio | 4.19 |
PB Ratio ranked
lower than
74.85%
of
819
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 227.39, Med: 2.64, Min: 0.05
CTLT:
4.19
Ranked among companies with meaningful PB Ratio only.
|
PB Ratio range over the past 10 years
Min: 2.84, Med: 5.4, Max: 8.48
Current: 4.19
|
| PS Ratio | 2.65 |
PS Ratio ranked
higher than
61.16%
of
775
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 9105.26, Med: 3.1, Min: 0.03
CTLT:
2.65
Ranked among companies with meaningful PS Ratio only.
|
PS Ratio range over the past 10 years
Min: 1.4, Med: 1.97, Max: 2.65
Current: 2.65
|
| Price-to-Free-Cash-Flow | 86.05 |
Price-to-Free-Cash-Flow ranked
higher than
56.38%
of
298
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 3143.75, Med: 30.84, Min: 0.23
CTLT:
86.05
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
|
Price-to-Free-Cash-Flow range over the past 10 years
Min: 23.66, Med: 34.82, Max: 256.24
Current: 86.05
|
| Price-to-Operating-Cash-Flow | 24.80 |
Price-to-Operating-Cash-Flow ranked
higher than
71.94%
of
392
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 14229.87, Med: 22, Min: 0.23
CTLT:
24.8
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
|
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 11.27, Med: 17.17, Max: 30.99
Current: 24.8
|
| EV-to-EBIT | 31.06 |
EV-to-EBIT ranked
lower than
73.43%
of
572
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 1015380.11, Med: 17.85, Min: 0.13
CTLT:
31.06
Ranked among companies with meaningful EV-to-EBIT only.
|
EV-to-EBIT range over the past 10 years
Min: 18, Med: 25.2, Max: 37.7
Current: 31.06
|
| EV-to-EBITDA | 17.16 |
EV-to-EBITDA ranked
lower than
56.95%
of
597
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 341528.02, Med: 15.24, Min: 0.12
CTLT:
17.16
Ranked among companies with meaningful EV-to-EBITDA only.
|
EV-to-EBITDA range over the past 10 years
Min: 11.5, Med: 15.3, Max: 22.2
Current: 17.16
|
| EV-to-Revenue | 3.50 |
EV-to-Revenue ranked
lower than
51.82%
of
795
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 23858.8, Med: 3.24, Min: 0.03
CTLT:
3.5
Ranked among companies with meaningful EV-to-Revenue only.
|
EV-to-Revenue range over the past 10 years
Min: 2.2, Med: 3, Max: 3.8
Current: 3.5
|
| PEG Ratio | 21.40 |
PEG Ratio ranked
lower than
100.00%
of
317
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 1472, Med: 1.93, Min: 0.07
CTLT:
21.4
Ranked among companies with meaningful PEG Ratio only.
|
PEG Ratio range over the past 10 years
Min: 9.66, Med: 28.47, Max: 70.96
Current: 21.4
|
| Current Ratio | 2.18 |
Current Ratio ranked
lower than
54.39%
of
855
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 413.44, Med: 2.39, Min: 0.02
CTLT:
2.18
Ranked among companies with meaningful Current Ratio only.
|
Current Ratio range over the past 10 years
Min: 1.51, Med: 1.96, Max: 2.91
Current: 2.18
|
| Quick Ratio | 1.71 |
Quick Ratio ranked
lower than
52.05%
of
855
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 413.44, Med: 1.87, Min: 0.02
CTLT:
1.71
Ranked among companies with meaningful Quick Ratio only.
|
Quick Ratio range over the past 10 years
Min: 1.14, Med: 1.53, Max: 2.49
Current: 1.71
|
| Days Inventory | 49.54 |
Days Inventory ranked
higher than
86.23%
of
755
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 950.68, Med: 119.8, Min: 0.2
CTLT:
49.54
Ranked among companies with meaningful Days Inventory only.
|
Days Inventory range over the past 10 years
Min: 19.07, Med: 40.19, Max: 49.54
Current: 49.54
|
| Days Sales Outstanding | 85.96 |
Days Sales Outstanding ranked
higher than
52.86%
of
770
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 864.61, Med: 81.76, Min: 0.1
CTLT:
85.96
Ranked among companies with meaningful Days Sales Outstanding only.
|
Days Sales Outstanding range over the past 10 years
Min: 72.58, Med: 80.62, Max: 85.97
Current: 85.96
|
| Days Payable | 43.55 |
Days Payable ranked
lower than
79.42%
of
758
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 952.38, Med: 76.32, Min: 0.04
CTLT:
43.55
Ranked among companies with meaningful Days Payable only.
|
Days Payable range over the past 10 years
Min: 38.5, Med: 41.93, Max: 44.69
Current: 43.55
|
Dividend & Buy Back
| Current | vs industry | vs history | |
|---|---|---|---|
| 3-Year Share Buyback Rate | -2.40 |
3-Year Share Buyback Rate ranked
lower than
74.26%
of
571
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 100, Med: -5.3, Min: -815
CTLT:
-2.4
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
|
3-Year Share Buyback Rate range over the past 10 years
Min: -2.4, Med: -2.1, Max: 0
Current: -2.4
|
Valuation & Return
| Current | vs industry | vs history | |
|---|---|---|---|
| Price-to-Projected-FCF | 3.23 |
Price-to-Intrinsic-Value-Projected-FCF ranked
lower than
72.73%
of
374
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 209, Med: 2.11, Min: 0.05
CTLT:
3.23
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
|
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 2.23, Med: 3.35, Max: 3.92
Current: 3.23
|
| Price-to-Median-PS-Value | 1.35 |
Price-to-Median-PS-Value ranked
lower than
66.22%
of
743
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 238.36, Med: 0.94, Min: 0.01
CTLT:
1.35
Ranked among companies with meaningful Price-to-Median-PS-Value only.
|
Price-to-Median-PS-Value range over the past 10 years
Min: 0.8, Med: 0.94, Max: 1.35
Current: 1.35
|
| Earnings Yield (Joel Greenblatt) % | 3.23 |
Earnings Yield (Greenblatt) ranked
higher than
51.56%
of
867
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 769.23, Med: 3.31, Min: -333.33
CTLT:
3.23
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
|
Earnings Yield (Greenblatt) range over the past 10 years
Min: 2.6, Med: 4, Max: 5.5
Current: 3.23
|
| Forward Rate of Return (Yacktman) % | 3.96 |
Forward Rate of Return ranked
lower than
70.07%
of
421
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 559.55, Med: 8.96, Min: -1635.32
CTLT:
3.96
Ranked among companies with meaningful Forward Rate of Return only.
|
Forward Rate of Return range over the past 10 years
Min: 2.6, Med: 3.9, Max: 8.5
Current: 3.96
|
More Statistics
| Revenue (TTM) (Mil) $ | 2,477.6 |
| EPS (TTM) $ | 1.06 |
| Beta | 2.02 |
| Volatility % | 40.31 |
| 52-Week Range $ | 29.23 - 47.04 |
| Shares Outstanding (Mil) | 145.72 |
Analyst Estimate
Piotroski F-Score Details
| Piotroski F-Score | 6 |
| Positive ROA | Y |
| Positive CFROA | Y |
| Higher ROA yoy | Y |
| CFROA > ROA | Y |
| Lower Leverage yoy | Y |
| Higher Current Ratio yoy | N |
| Less Shares Outstanding yoy | N |
| Higher Gross Margin yoy | Y |
| Higher Asset Turnover yoy | N |